Clinical outcomes of ALK + non-small cell lung cancer in Denmark

• DOI: 10.1080/0284186x.2023.2263153
• Publication Date: 2023-10-10T16:37:43Z
• Authors: Karin Holmskov Ha...; Jakob Sidenius Jo...; Edyta Maria Urbanska; Peter Meldgaard; Peter Hjorth-Hansen; Charlotte Kristia...; Miroslaw Stelmach; Eric Santoni-Rugiu; Maiken Parm Ulhøi; Anders Bondo Dyde...; Christina Dünweber; Jon Lykkegaard An...
• Keywords: ALK inhibitor

Background Real-world clinical outcomes of anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) patients vary. This study aimed to investigate the treatment and all ALK+ NSCLC in Denmark period 2011–2018, regardless disease stage.